FM NOVEMBER 2018 ISSUE - digital edition

More documents

Recommendations

Info

esearch SEPSIS: PATHOGEN AND HOST BATTLE Researchers found that in the onset and progression of sepsis, a protective mechanism normally present in the host was disabled SONIA FERNANDEZ A major cause of human disability and death throughout the world, sepsis is a condition that begins with an infection, progresses rapidly and can set off a chain of effects that result in multiple organ failure and irreparable damage to the body. Because of the condition’s rapid onset, physicians must respond immediately to the symptoms with broad-spectrum antibiotics for infection, drugs to combat inflammation and, in the more critical cases, vasopressors to manage shock. Because sepsis is so difficult to detect in its early stages, however, little has been known about how it develops. This may explain why no new effective drugs to treat sepsis have been developed in decades, while it remains one of the leading causes of hospital deaths. Sepsis also can result in serious disabilities for those who survive. Now, researchers at UC Santa Barbara, Sanford Prebys Medical Discovery Institute (SBP) in La Jolla, California, and UC San Diego have developed a method for tracking, on a molecular level, the development of sepsis. Their resulting discoveries could, in turn, lead to more advanced 76 / FUTURE MEDICINE / NOVEMBER 2018
therapies for sepsis that reduce its mortality, minimise the lifelong effects for survivors or even prevent the cascade of life-threatening effects before it begins, while reducing the billions of dollars spent every year to treat the condition. Their paper, “Accelerated Aging and Clearance of Host Anti-inflammatory Enzymes by Discrete Pathogens Fuels Sepsis” is published in the journal Cell Host & Microbe. “Sepsis is generally thought of as one singular disease, especially as it enters late stages,” said UC Santa Barbara biology professor Jamey Marth, who is the director of the campus’s Center for Nanomedicine, in addition to being a professor at SBP. “At this point, inflammation, and coagulopathy have caused the vascular and organ damage common to severe sepsis and septic shock. Our comparative approach to monitor the onset and progression of sepsis at the molecular level supports the view that there are different molecular pathways in sepsis depending on host responses to different pathogens.” New sepsis model In contrast to previous experimental models of sepsis, which typically release multiple and incompletely identified pathogens into the bloodstream, Marth and his team developed a more quantitative method that tracked the pathogen and host over time, beginning with infection. This method generated a reproducible protocol that allowed the scientists to map host responses, in this case to five different human pathogens representing common strains and isolates from different patients. In the study, Marth’s team found that in the onset and progression of sepsis caused by Salmonella or E. coli, a protective mechanism normally present in the host was disabled. The mechanism that the bacteria used included a means to accelerate the molecular aging and clearance of two anti-inflammatory alkaline phosphatase (AP) enzymes, called TNAP and IAP, which are normally present in the host bloodstream. This was achieved through pathogen activation of the host’s own Toll-like receptor-4 (TLR-4), and both pathogens were thus able to induce inflammatory compounds and reduce the likelihood of host survival. The scientists found that boosting the level of protective anti-inflammatory AP activity or using neuraminidase inhibitors to block the downstream IT’S POSSIBLE THAT SEPSIS IS SIMILAR TO CANCER, IN THAT WE NOW KNOW THAT CANCER IS A NOT A SINGLE DISEASE BUT REPRESENTS HUNDREDS OF DISEASES AT THE MOLECULAR LEVEL. effect of TLR-4 activation on NEU1 and NEU3 induction were both highly therapeutic approaches as inflammatory markers were reduced and host survival increased — indicating a potential direction for drug development. “It has been known that AP isozymes can reduce inflammation in the context of some diseases and pathogens — indeed AP is currently in clinical trials focused on inflammatory diseases, including colitis and sepsis,” said Won Ho Yang, Ph.D., lead author and a senior scientist in the Marth laboratory at both UCSB and SBP. “This study shows that the pathogen is interacting with the host to disable a protective response. The findings also demonstrate how both pathogen and host battle each other by altering the rates of protein aging and clearance — which itself is a newly discovered regulatory mechanism we recently reported that controls the half-lives of proteins in the blood.” In contrast, these responses weren’t seen in infections caused by other bacteria tested, including methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae. The different host responses, in this case, appeared divided between Gram-positive and Gram-negative bacteria, which describes the existence or the absence of an inflammatory compound found on Gram-negative strains. “We are continuing to map and compare host responses to different pathogens in sepsis, using state-ofthe-art technical approaches, and hope to ultimately stratify the disease,” said Marth, who is the Professor of Biochemistry and Molecular Biology at UC Santa Barbara, as well as the Mellichamp Chair of Systems Biology. “It’s possible that sepsis is similar to cancer, in that we now know that cancer is a not a single disease but represents hundreds of diseases at the molecular level.” Research on this project was also conducted by Douglas M. Heithoff, Peter V. Aziz, Benjamin Haslund- Gourley and Michael J. Mahan, SBP and UC Santa Barbara; Julia S. Westman, Sonoko Narisawa, Anthony B. Pinkerton and José Luis Millán, SBP; and Victor Nizet, M.D., UC San Diego. The research was supported by National Institutes of Health (NIH) Heart, Lung, and Blood Institute (HLBI) grants HL125352 and HL131474. Additional support was provided by the Swedish Research Council 2017-00192 and the Wille Family Foundation. —Reproduced with permission NOVEMBER 2018 / FUTURE MEDICINE / 77
Page 1:
₹ 250.00 VOL 5 | ISSUE 7 PAGES 10
Page 4 and 5:
Vol 5 Issue 7 November 2018 ₹ 250
Page 6 and 7:
REGULATORY DIAGNOSTICS HEAD & NECK
Page 8 and 9:
news updates Labels on fluoroquinol
Page 10 and 11:
the financial year 2018, it conduct
Page 12 and 13:
egulatory MCI IN DIRE STRAITS The f
Page 14 and 15:
drug resistance TACKLING EMERGING S
Page 16:
Three million surgeries and cancer
Page 19 and 20:
RIGHT DIAGNOSIS, RIGHT TREATMENT AC
Page 21 and 22:
PRICE CONTROL SCENARIO 1,30,000+ 20
Page 23 and 24:
LUNG CARCINOMA: THE COMMONEST CANCE
Page 25 and 26: oth neoadjuvant and adjuvant settin
Page 27 and 28: ates (45% vs 28%, respectively) com
Page 29 and 30: PHOTO: UMESH GOSWAMI Cancer immunot
Page 31 and 32: Oncologists, according to Dr Rajend
Page 33 and 34: ETED VACCINE THERAPY ON WAY in prec
Page 35 and 36: showed that rivaroxaban vascular do
Page 37 and 38: 1:1 to dacomitinib or gefitinib. A
Page 39 and 40: While Voretigene has passed clinica
Page 41 and 42: 1 2 3 4 The tumour was subtracted d
Page 43 and 44: occurring in less than 1% of the ge
Page 46 and 47: Ziehl-Neelsen staining of smears an
Page 48 and 49: case reports BRACHYTHERAPY FOR BRAI
Page 50 and 51: education NEUBERG-ANAND TO OFFER PO
Page 52: education BRIDGE COURSE AT CROSSROA
Page 55 and 56: to start the communication with a q
Page 57 and 58: DNA (mtDNAs) in a heteroplasmic mam
Page 60 and 61: policy MENTAL HEALTH CARE ACT 2017
Page 62 and 63: of the right of individual to seek
Page 64 and 65: COPD technology EBV INTERVENTION IN
Page 66: hospital news Continental Hospital
Page 69 and 70: in insurance coverage will lead to
Page 71 and 72: Environmental noise is an important
Page 73 and 74: BY SOURCE To reduce health effects,
Page 75: Hypertension is a common condition
Page 80: otator cuff tears has been shown to
Page 83 and 84: Zeiss laser tech to treat astigmati
Page 85 and 86: AUGUST 2018/ FUTURE MEDICINE / 85
Page 88: events MVR CANCON2018 debates trans
Page 91 and 92: science in India through research a
Page 93 and 94: will make a double strand break of
Page 95 and 96: ook review A REBUTTAL TO VACCINE NA
Page 98 and 99: DON’T RESTRICT YOURSELF TO ‘DOT
show all

FM NOVEMBER 2018 ISSUE - digital edition

Create successful ePaper yourself

Delete template?

Save as template?